Serotonin neurons in the dorsal raphe mediate the anticataplectic action of orexin neurons by reducing amygdala activity. 2017

Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
Department of Molecular Neuroscience and Integrative Physiology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-8640, Japan.

Narcolepsy is a sleep disorder caused by the loss of orexin (hypocretin)-producing neurons and marked by excessive daytime sleepiness and a sudden weakening of muscle tone, or cataplexy, often triggered by strong emotions. In a mouse model for narcolepsy, we previously demonstrated that serotonin neurons of the dorsal raphe nucleus (DRN) mediate the suppression of cataplexy-like episodes (CLEs) by orexin neurons. Using an optogenetic tool, in this paper we show that the acute activation of DRN serotonin neuron terminals in the amygdala, but not in nuclei involved in regulating rapid eye-movement sleep and atonia, suppressed CLEs. Not only did stimulating serotonin nerve terminals reduce amygdala activity, but the chemogenetic inhibition of the amygdala using designer receptors exclusively activated by designer drugs also drastically decreased CLEs, whereas chemogenetic activation increased them. Moreover, the optogenetic inhibition of serotonin nerve terminals in the amygdala blocked the anticataplectic effects of orexin signaling in DRN serotonin neurons. Taken together, the results suggest that DRN serotonin neurons, as a downstream target of orexin neurons, inhibit cataplexy by reducing the activity of amygdala as a center for emotional processing.

UI MeSH Term Description Entries
D008297 Male Males
D002375 Catalepsy A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. The limbs tend to remain in whatever position they are placed (waxy flexibility). Catalepsy may be associated with PSYCHOTIC DISORDERS (e.g., SCHIZOPHRENIA, CATATONIC), nervous system drug toxicity, and other conditions. Cerea Flexibilitas,Flexibility, Waxy,Anochlesia,Anochlesias,Catalepsies,Flexibilitas, Cerea,Flexibilities, Waxy,Waxy Flexibilities,Waxy Flexibility
D005133 Eye Movements Voluntary or reflex-controlled movements of the eye. Eye Movement,Movement, Eye,Movements, Eye
D000679 Amygdala Almond-shaped group of basal nuclei anterior to the INFERIOR HORN OF THE LATERAL VENTRICLE of the TEMPORAL LOBE. The amygdala is part of the limbic system. Amygdaloid Body,Amygdaloid Nuclear Complex,Amygdaloid Nucleus,Archistriatum,Corpus Amygdaloideum,Intercalated Amygdaloid Nuclei,Massa Intercalata,Nucleus Amygdalae,Amygdalae, Nucleus,Amygdaloid Bodies,Amygdaloid Nuclear Complices,Amygdaloid Nuclei, Intercalated,Amygdaloid Nucleus, Intercalated,Amygdaloideum, Corpus,Amygdaloideums, Corpus,Archistriatums,Complex, Amygdaloid Nuclear,Complices, Amygdaloid Nuclear,Corpus Amygdaloideums,Intercalata, Massa,Intercalatas, Massa,Intercalated Amygdaloid Nucleus,Massa Intercalatas,Nuclear Complex, Amygdaloid,Nuclear Complices, Amygdaloid,Nuclei, Intercalated Amygdaloid,Nucleus, Amygdaloid,Nucleus, Intercalated Amygdaloid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D059326 Serotonergic Neurons Neurons whose primary neurotransmitter is SEROTONIN. Serotoninergic Neurons,Neuron, Serotonergic,Neuron, Serotoninergic,Neurons, Serotonergic,Neurons, Serotoninergic,Serotonergic Neuron,Serotoninergic Neuron
D018345 Mice, Knockout Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes. Knockout Mice,Mice, Knock-out,Mouse, Knockout,Knock-out Mice,Knockout Mouse,Mice, Knock out

Related Publications

Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
February 2018, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
October 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
August 1985, Brain research bulletin,
Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
March 2005, Regulatory peptides,
Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
November 2012, The Journal of physiology,
Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
July 1984, Life sciences,
Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
April 2020, Journal of psychopharmacology (Oxford, England),
Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
August 2022, Neuron,
Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
October 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Emi Hasegawa, and Takashi Maejima, and Takayuki Yoshida, and Olivia A Masseck, and Stefan Herlitze, and Mitsuhiro Yoshioka, and Takeshi Sakurai, and Michihiro Mieda
June 2019, Neuropeptides,
Copied contents to your clipboard!